Tag: cell and gene therapy clinical trial services market analysis

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Cell And Gene Therapy Clinical Trial Services Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for clinical trial services in cell and gene therapies has experienced substantial expansion recently, projecting a rise from $4.18 billion in 2025 to $4.62 billion in 2026, reflecting a compound annual growth rate of 10.3%. This upswing during the historical period is underpinned by a surge in cell and gene therapy clinical trials, a greater reliance on specialized contract research organizations (CROs), the increasing intricacy of trial protocols, an amplified focus on rare disease studies, and heightened regulatory scrutiny of cutting-edge therapeutic approaches.

The market for cell and gene therapy clinical trial services is projected for substantial expansion, anticipated to reach $6.44 billion by 2030, reflecting an 8.7% compound annual growth rate (CAGR). This upward trajectory over the forecast period stems from several key factors, including a heightened demand for late-stage clinical trial support, the escalating use of digital technologies in trials, broadened efforts in global patient recruitment, a greater emphasis on incorporating real-world evidence, and increased financial commitments towards precision clinical research. Dominant trends shaping this market include a growing embrace of decentralized clinical trial methodologies, the increasing utilization of digital platforms for patient recruitment, the seamless integration of sophisticated data management systems, the expansion of international trial site networks, and a more pronounced attention to regulatory adherence and trial precision.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

#Cell And Gene Therapy Clinical Trial Services Market Growth Factors: Which Forces Are Supporting Market Expansion?

The increasing prevalence of genetic disorders is anticipated to be a significant catalyst for the expansion of the cell and gene therapy clinical trial services sector. These genetic conditions, stemming from alterations in an individual’s deoxyribonucleic acid or genetic makeup, are becoming more common due to several contributing elements such as enhanced accessibility to genetic screening, the natural occurrence of genetic mutations, and the continued practice of marriages between closely related individuals. Services within cell and gene therapy clinical trials are designed to combat this surge in genetic diseases by fostering the creation of innovative therapeutic strategies, enabling personalized treatment plans, expediting the transition of scientific discoveries into clinical applications, and broadening the therapeutic avenues for individuals affected by genetic conditions. As an illustration, the National Health Service in the United Kingdom reported in 2023 that sickle cell disorder holds the distinction of being the most prevalent inherited condition in England, affecting approximately 17,000 individuals (NHSE, 2023). Consequently, the escalating occurrence of genetic diseases is directly fueling the growth trajectory of the market for cell and gene therapy clinical trial services.

Cell And Gene Therapy Clinical Trial Services Market Segment Analysis And Revenue Opportunities

The cell and gene therapy clinical trial services market covered in this report is segmented –

1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

Cell And Gene Therapy Clinical Trial Services Market Industry Trends: What Changes Are Reshaping Demand?

In the cell and gene therapy clinical trial services arena, leading entities are prioritizing the integration of cutting-edge technology, specifically customer relationship management (CRM) systems, to enhance operational effectiveness and secure market superiority. The CRM systems employed within cell and gene therapy clinical trial services are designed to optimize and synchronize all communications with trial participants, medical professionals, and other involved parties across the lifecycle of a clinical trial. Demonstrating this trend, AmerisourceBergen Corporation, a prominent healthcare firm based in the United States, introduced its Cell and Gene Therapy (CGT) Integration Hub in April 2023. This newly launched platform is engineered to foster greater interconnectedness and simplify workflows within the entire cell and gene therapy treatment continuum. Leveraging AmerisourceBergen’s established CRM infrastructure, the CGT Integration Hub endeavors to expedite the journey to care, partly by furnishing physicians and patient support teams with improved transparency concerning the development and administration phases of these advanced therapies. With functionalities encompassing accelerated benefits verification, live progress monitoring, and preemptive notifications, the CGT Integration Hub is geared towards simplifying the coordination of care, reducing obstacles, and ultimately elevating the overall experience for both patients and providers involved in the delivery of cell and gene therapies.

Cell And Gene Therapy Clinical Trial Services Market Leading Players Shaping Industry Direction

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

Access The Complete Cell And Gene Therapy Clinical Trial Services Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Cell And Gene Therapy Clinical Trial Services Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for clinical trial services in cell and gene therapies has experienced substantial expansion recently, projecting a rise from $4.18 billion in 2025 to $4.62 billion in 2026, reflecting a compound annual growth rate of 10.3%. This upswing during the historical period is underpinned by a surge in cell and gene therapy clinical trials, a greater reliance on specialized contract research organizations (CROs), the increasing intricacy of trial protocols, an amplified focus on rare disease studies, and heightened regulatory scrutiny of cutting-edge therapeutic approaches.

The market for cell and gene therapy clinical trial services is projected for substantial expansion, anticipated to reach $6.44 billion by 2030, reflecting an 8.7% compound annual growth rate (CAGR). This upward trajectory over the forecast period stems from several key factors, including a heightened demand for late-stage clinical trial support, the escalating use of digital technologies in trials, broadened efforts in global patient recruitment, a greater emphasis on incorporating real-world evidence, and increased financial commitments towards precision clinical research. Dominant trends shaping this market include a growing embrace of decentralized clinical trial methodologies, the increasing utilization of digital platforms for patient recruitment, the seamless integration of sophisticated data management systems, the expansion of international trial site networks, and a more pronounced attention to regulatory adherence and trial precision.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

#Cell And Gene Therapy Clinical Trial Services Market Growth Factors: Which Forces Are Supporting Market Expansion?

The increasing prevalence of genetic disorders is anticipated to be a significant catalyst for the expansion of the cell and gene therapy clinical trial services sector. These genetic conditions, stemming from alterations in an individual’s deoxyribonucleic acid or genetic makeup, are becoming more common due to several contributing elements such as enhanced accessibility to genetic screening, the natural occurrence of genetic mutations, and the continued practice of marriages between closely related individuals. Services within cell and gene therapy clinical trials are designed to combat this surge in genetic diseases by fostering the creation of innovative therapeutic strategies, enabling personalized treatment plans, expediting the transition of scientific discoveries into clinical applications, and broadening the therapeutic avenues for individuals affected by genetic conditions. As an illustration, the National Health Service in the United Kingdom reported in 2023 that sickle cell disorder holds the distinction of being the most prevalent inherited condition in England, affecting approximately 17,000 individuals (NHSE, 2023). Consequently, the escalating occurrence of genetic diseases is directly fueling the growth trajectory of the market for cell and gene therapy clinical trial services.

Cell And Gene Therapy Clinical Trial Services Market Segment Analysis And Revenue Opportunities

The cell and gene therapy clinical trial services market covered in this report is segmented –

1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

Cell And Gene Therapy Clinical Trial Services Market Industry Trends: What Changes Are Reshaping Demand?

In the cell and gene therapy clinical trial services arena, leading entities are prioritizing the integration of cutting-edge technology, specifically customer relationship management (CRM) systems, to enhance operational effectiveness and secure market superiority. The CRM systems employed within cell and gene therapy clinical trial services are designed to optimize and synchronize all communications with trial participants, medical professionals, and other involved parties across the lifecycle of a clinical trial. Demonstrating this trend, AmerisourceBergen Corporation, a prominent healthcare firm based in the United States, introduced its Cell and Gene Therapy (CGT) Integration Hub in April 2023. This newly launched platform is engineered to foster greater interconnectedness and simplify workflows within the entire cell and gene therapy treatment continuum. Leveraging AmerisourceBergen’s established CRM infrastructure, the CGT Integration Hub endeavors to expedite the journey to care, partly by furnishing physicians and patient support teams with improved transparency concerning the development and administration phases of these advanced therapies. With functionalities encompassing accelerated benefits verification, live progress monitoring, and preemptive notifications, the CGT Integration Hub is geared towards simplifying the coordination of care, reducing obstacles, and ultimately elevating the overall experience for both patients and providers involved in the delivery of cell and gene therapies.

Cell And Gene Therapy Clinical Trial Services Market Leading Players Shaping Industry Direction

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

Access The Complete Cell And Gene Therapy Clinical Trial Services Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Cell And Gene Therapy Clinical Trial Services Market Growth Analysis: How Will Revenue Expand During The Forecast Period?

The market for clinical trial services in cell and gene therapies has experienced substantial expansion recently, projecting a rise from $4.18 billion in 2025 to $4.62 billion in 2026, reflecting a compound annual growth rate of 10.3%. This upswing during the historical period is underpinned by a surge in cell and gene therapy clinical trials, a greater reliance on specialized contract research organizations (CROs), the increasing intricacy of trial protocols, an amplified focus on rare disease studies, and heightened regulatory scrutiny of cutting-edge therapeutic approaches.

The market for cell and gene therapy clinical trial services is projected for substantial expansion, anticipated to reach $6.44 billion by 2030, reflecting an 8.7% compound annual growth rate (CAGR). This upward trajectory over the forecast period stems from several key factors, including a heightened demand for late-stage clinical trial support, the escalating use of digital technologies in trials, broadened efforts in global patient recruitment, a greater emphasis on incorporating real-world evidence, and increased financial commitments towards precision clinical research. Dominant trends shaping this market include a growing embrace of decentralized clinical trial methodologies, the increasing utilization of digital platforms for patient recruitment, the seamless integration of sophisticated data management systems, the expansion of international trial site networks, and a more pronounced attention to regulatory adherence and trial precision.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

#Cell And Gene Therapy Clinical Trial Services Market Growth Factors: Which Forces Are Supporting Market Expansion?

The increasing prevalence of genetic disorders is anticipated to be a significant catalyst for the expansion of the cell and gene therapy clinical trial services sector. These genetic conditions, stemming from alterations in an individual’s deoxyribonucleic acid or genetic makeup, are becoming more common due to several contributing elements such as enhanced accessibility to genetic screening, the natural occurrence of genetic mutations, and the continued practice of marriages between closely related individuals. Services within cell and gene therapy clinical trials are designed to combat this surge in genetic diseases by fostering the creation of innovative therapeutic strategies, enabling personalized treatment plans, expediting the transition of scientific discoveries into clinical applications, and broadening the therapeutic avenues for individuals affected by genetic conditions. As an illustration, the National Health Service in the United Kingdom reported in 2023 that sickle cell disorder holds the distinction of being the most prevalent inherited condition in England, affecting approximately 17,000 individuals (NHSE, 2023). Consequently, the escalating occurrence of genetic diseases is directly fueling the growth trajectory of the market for cell and gene therapy clinical trial services.

Cell And Gene Therapy Clinical Trial Services Market Segment Analysis And Revenue Opportunities

The cell and gene therapy clinical trial services market covered in this report is segmented –

1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

Cell And Gene Therapy Clinical Trial Services Market Industry Trends: What Changes Are Reshaping Demand?

In the cell and gene therapy clinical trial services arena, leading entities are prioritizing the integration of cutting-edge technology, specifically customer relationship management (CRM) systems, to enhance operational effectiveness and secure market superiority. The CRM systems employed within cell and gene therapy clinical trial services are designed to optimize and synchronize all communications with trial participants, medical professionals, and other involved parties across the lifecycle of a clinical trial. Demonstrating this trend, AmerisourceBergen Corporation, a prominent healthcare firm based in the United States, introduced its Cell and Gene Therapy (CGT) Integration Hub in April 2023. This newly launched platform is engineered to foster greater interconnectedness and simplify workflows within the entire cell and gene therapy treatment continuum. Leveraging AmerisourceBergen’s established CRM infrastructure, the CGT Integration Hub endeavors to expedite the journey to care, partly by furnishing physicians and patient support teams with improved transparency concerning the development and administration phases of these advanced therapies. With functionalities encompassing accelerated benefits verification, live progress monitoring, and preemptive notifications, the CGT Integration Hub is geared towards simplifying the coordination of care, reducing obstacles, and ultimately elevating the overall experience for both patients and providers involved in the delivery of cell and gene therapies.

Cell And Gene Therapy Clinical Trial Services Market Leading Players Shaping Industry Direction

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

Access The Complete Cell And Gene Therapy Clinical Trial Services Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Clinical Trial Services Market Regional Outlook: Where Are The Largest Opportunities Located?

North Americawas the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Cell And Gene Therapy Clinical Trial Services Market Projected To Reach By 2030?

The size of the cell and gene therapy clinical trial services market has experienced rapid expansion in recent years. It is expected to grow from $4.18 billion in 2025 to $4.62 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. The market’s growth during the preceding period can be attributed to an increasing number of cell and gene therapy clinical trials, a rise in outsourcing to specialized CROs, the growing complexity of trial designs, an expansion of rare disease research, and enhanced regulatory oversight of advanced therapies.

The cell and gene therapy clinical trial services market size is anticipated to undergo significant growth in the coming years. It is projected to reach $6.44 billion by 2030, progressing at a compound annual growth rate (CAGR) of 8.7%. This expansion within the forecast period can be attributed to several factors, such as the increasing demand for late-stage clinical trial services, the rising adoption of digital trial technologies, the expansion of global patient recruitment initiatives, a growing emphasis on real-world evidence integration, and increasing investments in precision clinical research. Prominent trends expected in the forecast period include the increasing adoption of decentralized clinical trial models, the growing use of digital patient recruitment platforms, the rising integration of advanced data management systems, the expansion of global trial site networks, and an enhanced focus on regulatory compliance and trial accuracy.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

What Major Factors Are Driving The Cell And Gene Therapy Clinical Trial Services Market Forward?

The increasing occurrence of genetic conditions is anticipated to drive expansion in the cell and gene therapy clinical trial services market moving ahead. These diseases stem from alterations in an individual’s DNA or genetic makeup. Several factors contribute to this growing prevalence, such as broader access to genetic testing, the presence of genetic mutations, and a higher rate of consanguineous marriages. By fostering the creation of new treatments, customizing therapies for individuals, speeding up the application of research in clinical settings, and broadening choices for those with genetic disorders, cell and gene therapy clinical trial services tackle the increasing incidence of these conditions. An example illustrates this: in 2023, the National Health Service (a UK government department) reported that sickle cell disorder (SCD) was England’s most common genetic condition, affecting approximately 17,000 individuals (NHSE, 2023). Consequently, the escalating occurrence of genetic diseases is a key factor propelling the expansion of the cell and gene therapy clinical trial services market.

What Are The Different Segment Types In The Cell And Gene Therapy Clinical Trial Services Market Segment Breakdown?

The cell and gene therapy clinical trial services market covered in this report is segmented –

1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

Which Trends Are Impacting The Progress Of The Cell And Gene Therapy Clinical Trial Services Market?

Leading companies within the cell and gene therapy clinical trial services market are dedicating efforts to implementing advanced technology, specifically customer relationship management systems, to boost efficiency and secure a competitive edge. This customer relationship management approach streamlines and coordinates interactions with trial participants, healthcare providers, and other stakeholders throughout the clinical trial process. For example, in April 2023, AmerisourceBergen Corporation, a US-based healthcare company, unveiled the Cell and Gene Therapy (CGT) Integration Hub. This platform aims to enhance connectivity and streamline processes across the cell and gene therapy treatment pathway. Backed by AmerisourceBergen’s customer relationship management (CRM) system, it seeks to simplify the path-to-care process, partly by providing physicians and patient services teams with greater visibility throughout the therapy’s development and delivery. The CGT Integration Hub, which incorporates features such as expedited benefits investigation, real-time status tracking, and proactive alerts, is designed to simplify care coordination, reduce barriers, and improve the overall patient and provider experience when delivering cell and gene therapies.

Who Are The Well-Known Companies In The Cell And Gene Therapy Clinical Trial Services Market?

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

Get The Full Cell And Gene Therapy Clinical Trial Services Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Where Is The Cell And Gene Therapy Clinical Trial Services Market Primarily Concentrated By Region?

North America was the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cell And Gene Therapy Clinical Trial Services Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Browse Through More Reports Similar to the Global Cell And Gene Therapy Clinical Trial Services Market 2026, By The Business Research Company

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell And Gene Therapy Manufacturing Services Market 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-market

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

From Its 2026 Market Size, What Value Is The Cell And Gene Therapy Clinical Trial Services Market Projected To Reach By 2030?

The size of the cell and gene therapy clinical trial services market has experienced rapid expansion in recent years. It is expected to grow from $4.18 billion in 2025 to $4.62 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.3%. The market’s growth during the preceding period can be attributed to an increasing number of cell and gene therapy clinical trials, a rise in outsourcing to specialized CROs, the growing complexity of trial designs, an expansion of rare disease research, and enhanced regulatory oversight of advanced therapies.

The cell and gene therapy clinical trial services market size is anticipated to undergo significant growth in the coming years. It is projected to reach $6.44 billion by 2030, progressing at a compound annual growth rate (CAGR) of 8.7%. This expansion within the forecast period can be attributed to several factors, such as the increasing demand for late-stage clinical trial services, the rising adoption of digital trial technologies, the expansion of global patient recruitment initiatives, a growing emphasis on real-world evidence integration, and increasing investments in precision clinical research. Prominent trends expected in the forecast period include the increasing adoption of decentralized clinical trial models, the growing use of digital patient recruitment platforms, the rising integration of advanced data management systems, the expansion of global trial site networks, and an enhanced focus on regulatory compliance and trial accuracy.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

What Major Factors Are Driving The Cell And Gene Therapy Clinical Trial Services Market Forward?

The increasing occurrence of genetic conditions is anticipated to drive expansion in the cell and gene therapy clinical trial services market moving ahead. These diseases stem from alterations in an individual’s DNA or genetic makeup. Several factors contribute to this growing prevalence, such as broader access to genetic testing, the presence of genetic mutations, and a higher rate of consanguineous marriages. By fostering the creation of new treatments, customizing therapies for individuals, speeding up the application of research in clinical settings, and broadening choices for those with genetic disorders, cell and gene therapy clinical trial services tackle the increasing incidence of these conditions. An example illustrates this: in 2023, the National Health Service (a UK government department) reported that sickle cell disorder (SCD) was England’s most common genetic condition, affecting approximately 17,000 individuals (NHSE, 2023). Consequently, the escalating occurrence of genetic diseases is a key factor propelling the expansion of the cell and gene therapy clinical trial services market.

What Are The Different Segment Types In The Cell And Gene Therapy Clinical Trial Services Market Segment Breakdown?

The cell and gene therapy clinical trial services market covered in this report is segmented –

1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

Which Trends Are Impacting The Progress Of The Cell And Gene Therapy Clinical Trial Services Market?

Leading companies within the cell and gene therapy clinical trial services market are dedicating efforts to implementing advanced technology, specifically customer relationship management systems, to boost efficiency and secure a competitive edge. This customer relationship management approach streamlines and coordinates interactions with trial participants, healthcare providers, and other stakeholders throughout the clinical trial process. For example, in April 2023, AmerisourceBergen Corporation, a US-based healthcare company, unveiled the Cell and Gene Therapy (CGT) Integration Hub. This platform aims to enhance connectivity and streamline processes across the cell and gene therapy treatment pathway. Backed by AmerisourceBergen’s customer relationship management (CRM) system, it seeks to simplify the path-to-care process, partly by providing physicians and patient services teams with greater visibility throughout the therapy’s development and delivery. The CGT Integration Hub, which incorporates features such as expedited benefits investigation, real-time status tracking, and proactive alerts, is designed to simplify care coordination, reduce barriers, and improve the overall patient and provider experience when delivering cell and gene therapies.

Who Are The Well-Known Companies In The Cell And Gene Therapy Clinical Trial Services Market?

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

Get The Full Cell And Gene Therapy Clinical Trial Services Market Report:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Where Is The Cell And Gene Therapy Clinical Trial Services Market Primarily Concentrated By Region?

North America was the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Cell And Gene Therapy Clinical Trial Services Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Browse Through More Reports Similar to the Global Cell And Gene Therapy Clinical Trial Services Market 2026, By The Business Research Company

Cell And Gene Therapy Supply Chain Or Logistics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell And Gene Therapy Manufacturing Services Market 2026

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-manufacturing-services-market

Genes Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Cell And Gene Therapy Clinical Trial Services Market Projected To Become By 2030 Based On Its 2026 Valuation?

The cell and gene therapy clinical trial services market has experienced significant expansion in recent years. It is anticipated to grow from $4.18 billion in 2025 to $4.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historic period was driven by an escalating number of cell and gene therapy clinical trials, an increase in outsourcing to specialized CROs, the evolving complexity of trial designs, the broadening scope of rare disease research, and heightened regulatory oversight of advanced therapies.

The cell and gene therapy clinical trial services market is projected to experience robust expansion over the coming years. It is anticipated to reach $6.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This projected increase throughout the forecast period stems from factors such as a heightened demand for late-stage clinical trial services, greater embrace of digital trial technologies, broader global patient recruitment efforts, an intensified focus on incorporating real-world evidence, and increased funding in precision clinical research. Key developments expected during this timeframe involve a rise in decentralized clinical trial models, wider deployment of digital patient recruitment platforms, enhanced integration of sophisticated data management systems, the broadening of global trial site networks, and a reinforced emphasis on regulatory adherence and trial precision.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

What Primary Drivers Are Shaping The Development Of The Cell And Gene Therapy Clinical Trial Services Market?

The increasing occurrence of genetic conditions is projected to boost the expansion of the cell and gene therapy clinical trial services market in the future. These are health problems resulting from alterations in an individual’s DNA or genetic makeup. Several factors contribute to the growing frequency of genetic diseases, such as greater access to genetic testing, the emergence of genetic mutations, and the common practice of consanguineous marriage. Cell and gene therapy clinical trial services are crucial in tackling the rising prevalence of genetic diseases by fostering the creation of new treatments, customizing therapies for patients, expediting the transition of research into clinical application, and broadening the therapeutic choices for those with genetic disorders. For example, in 2023, data from the National Health Service, a UK government body, indicated that in England, sickle cell disorder (SCD) stands as the most common genetic condition, affecting approximately 17,000 individuals (NHSE, 2023). Consequently, the growing incidence of genetic disease acts as a key driver for the growth of the cell and gene therapy clinical trial services market.

What Segment Groups Are Identified Within The Cell And Gene Therapy Clinical Trial Services Market?

The cell and gene therapy clinical trial services market covered in this report is segmented –

1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

What Major Market Trends Are Driving Changes In The Cell And Gene Therapy Clinical Trial Services Market?

Major companies within the cell and gene therapy clinical trial services market are concentrating their efforts on deploying advanced technology, including customer relationship management systems, to enhance efficiency and gain a competitive edge. The customer relationship management system, as employed by cell and gene therapy clinical trial services, streamlines and synchronizes interactions with trial participants, healthcare providers, and other stakeholders across the entire clinical trial process. For instance, in April 2023, AmerisourceBergen Corporation, a healthcare company based in the US, unveiled the Cell and Gene Therapy (CGT) Integration Hub, a platform intended to improve connectivity and rationalize processes throughout the cell and gene therapy treatment pathway. This platform, which is underpinned by AmerisourceBergen’s customer relationship management (CRM) system, endeavors to simplify the path-to-care process, partly by providing physicians and patient services teams with greater visibility across the therapy development and delivery journey. The CGT Integration Hub, featuring elements like expedited benefits investigation, real-time status tracking, and proactive alerts, is designed to simplify care coordination, minimize impediments, and enhance the overall patient and provider experience when delivering cell and gene therapies.

Which Companies Hold Significant Positions In The Cell And Gene Therapy Clinical Trial Services Market?

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

Read the full cell and gene therapy clinical trial services market report here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

How Does The Cell And Gene Therapy Clinical Trial Services Market Perform Across Major Global Regions?

North America was the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell And Gene Therapy Clinical Trial Services Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15535&type=smp

Browse Through More Reports Similar to the Global Cell And Gene Therapy Clinical Trial Services Market 2026, By The Business Research Company

Cell And Gene Therapy Supply Chain Or Logistics Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell And Gene Therapy Clinical Trial Services Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Contract Development And Manufacturing Organization Cdmo Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Cell And Gene Therapy Clinical Trial Services Market Projected To Become By 2030 Based On Its 2026 Valuation?

The cell and gene therapy clinical trial services market has experienced significant expansion in recent years. It is anticipated to grow from $4.18 billion in 2025 to $4.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historic period was driven by an escalating number of cell and gene therapy clinical trials, an increase in outsourcing to specialized CROs, the evolving complexity of trial designs, the broadening scope of rare disease research, and heightened regulatory oversight of advanced therapies.

The cell and gene therapy clinical trial services market is projected to experience robust expansion over the coming years. It is anticipated to reach $6.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This projected increase throughout the forecast period stems from factors such as a heightened demand for late-stage clinical trial services, greater embrace of digital trial technologies, broader global patient recruitment efforts, an intensified focus on incorporating real-world evidence, and increased funding in precision clinical research. Key developments expected during this timeframe involve a rise in decentralized clinical trial models, wider deployment of digital patient recruitment platforms, enhanced integration of sophisticated data management systems, the broadening of global trial site networks, and a reinforced emphasis on regulatory adherence and trial precision.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

What Primary Drivers Are Shaping The Development Of The Cell And Gene Therapy Clinical Trial Services Market?

The increasing occurrence of genetic conditions is projected to boost the expansion of the cell and gene therapy clinical trial services market in the future. These are health problems resulting from alterations in an individual’s DNA or genetic makeup. Several factors contribute to the growing frequency of genetic diseases, such as greater access to genetic testing, the emergence of genetic mutations, and the common practice of consanguineous marriage. Cell and gene therapy clinical trial services are crucial in tackling the rising prevalence of genetic diseases by fostering the creation of new treatments, customizing therapies for patients, expediting the transition of research into clinical application, and broadening the therapeutic choices for those with genetic disorders. For example, in 2023, data from the National Health Service, a UK government body, indicated that in England, sickle cell disorder (SCD) stands as the most common genetic condition, affecting approximately 17,000 individuals (NHSE, 2023). Consequently, the growing incidence of genetic disease acts as a key driver for the growth of the cell and gene therapy clinical trial services market.

What Segment Groups Are Identified Within The Cell And Gene Therapy Clinical Trial Services Market?

The cell and gene therapy clinical trial services market covered in this report is segmented –

1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

What Major Market Trends Are Driving Changes In The Cell And Gene Therapy Clinical Trial Services Market?

Major companies within the cell and gene therapy clinical trial services market are concentrating their efforts on deploying advanced technology, including customer relationship management systems, to enhance efficiency and gain a competitive edge. The customer relationship management system, as employed by cell and gene therapy clinical trial services, streamlines and synchronizes interactions with trial participants, healthcare providers, and other stakeholders across the entire clinical trial process. For instance, in April 2023, AmerisourceBergen Corporation, a healthcare company based in the US, unveiled the Cell and Gene Therapy (CGT) Integration Hub, a platform intended to improve connectivity and rationalize processes throughout the cell and gene therapy treatment pathway. This platform, which is underpinned by AmerisourceBergen’s customer relationship management (CRM) system, endeavors to simplify the path-to-care process, partly by providing physicians and patient services teams with greater visibility across the therapy development and delivery journey. The CGT Integration Hub, featuring elements like expedited benefits investigation, real-time status tracking, and proactive alerts, is designed to simplify care coordination, minimize impediments, and enhance the overall patient and provider experience when delivering cell and gene therapies.

Which Companies Hold Significant Positions In The Cell And Gene Therapy Clinical Trial Services Market?

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

Read the full cell and gene therapy clinical trial services market report here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

How Does The Cell And Gene Therapy Clinical Trial Services Market Perform Across Major Global Regions?

North America was the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell And Gene Therapy Clinical Trial Services Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15535&type=smp

Browse Through More Reports Similar to the Global Cell And Gene Therapy Clinical Trial Services Market 2026, By The Business Research Company

Cell And Gene Therapy Supply Chain Or Logistics Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell And Gene Therapy Clinical Trial Services Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Contract Development And Manufacturing Organization Cdmo Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Cell And Gene Therapy Clinical Trial Services Market Projected To Become By 2030 Based On Its 2026 Valuation?

The cell and gene therapy clinical trial services market has experienced significant expansion in recent years. It is anticipated to grow from $4.18 billion in 2025 to $4.62 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historic period was driven by an escalating number of cell and gene therapy clinical trials, an increase in outsourcing to specialized CROs, the evolving complexity of trial designs, the broadening scope of rare disease research, and heightened regulatory oversight of advanced therapies.

The cell and gene therapy clinical trial services market is projected to experience robust expansion over the coming years. It is anticipated to reach $6.44 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. This projected increase throughout the forecast period stems from factors such as a heightened demand for late-stage clinical trial services, greater embrace of digital trial technologies, broader global patient recruitment efforts, an intensified focus on incorporating real-world evidence, and increased funding in precision clinical research. Key developments expected during this timeframe involve a rise in decentralized clinical trial models, wider deployment of digital patient recruitment platforms, enhanced integration of sophisticated data management systems, the broadening of global trial site networks, and a reinforced emphasis on regulatory adherence and trial precision.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15535&type=smp

What Primary Drivers Are Shaping The Development Of The Cell And Gene Therapy Clinical Trial Services Market?

The increasing occurrence of genetic conditions is projected to boost the expansion of the cell and gene therapy clinical trial services market in the future. These are health problems resulting from alterations in an individual’s DNA or genetic makeup. Several factors contribute to the growing frequency of genetic diseases, such as greater access to genetic testing, the emergence of genetic mutations, and the common practice of consanguineous marriage. Cell and gene therapy clinical trial services are crucial in tackling the rising prevalence of genetic diseases by fostering the creation of new treatments, customizing therapies for patients, expediting the transition of research into clinical application, and broadening the therapeutic choices for those with genetic disorders. For example, in 2023, data from the National Health Service, a UK government body, indicated that in England, sickle cell disorder (SCD) stands as the most common genetic condition, affecting approximately 17,000 individuals (NHSE, 2023). Consequently, the growing incidence of genetic disease acts as a key driver for the growth of the cell and gene therapy clinical trial services market.

What Segment Groups Are Identified Within The Cell And Gene Therapy Clinical Trial Services Market?

The cell and gene therapy clinical trial services market covered in this report is segmented –

1) By Service: Clinical Trial Design And Planning, Supply And Logistic Services, Regulatory Affairs And Compliance, Data Management And Biostatics, Site Management And Monitoring, Other Services

2) By Therapy Type: Gene Therapy, Cell Therapy, Gene Modified Cell Therapy

3) By Indication: Oncology, Hematology, Metabolic Disorders, Infectious Diseases, Neurology, Cardiovascular Diseases, Musculoskeletal Disorders, Other Indications

4) By End-Use: Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic And Research Institutes, Other End-Users

Subsegments:

1) By Clinical Trial Design And Planning: Protocol Development, Trial Feasibility Studies, Trial Design Consultation, Patient Recruitment And Enrollment Strategy, Risk-Based Monitoring Plans

2) By Supply And Logistic Services: Clinical Trial Supply Chain Management, Cold Chain Logistics, Packaging And Labeling Services, Transportation And Distribution Of Biological Samples, Customs And Import/Export Services

3) By Regulatory Affairs And Compliance: Regulatory Strategy And Consulting, Regulatory Submission And Documentation, Compliance With GMP (Good Manufacturing Practices), Regulatory Pathway Consultation, Clinical Trial Applications (CTAs)

4) By Data Management And Biostatistics: Clinical Data Management (CDM), Statistical Analysis And Reporting, Clinical Data Monitoring, Data Integration And Validation, Electronic Data Capture (EDC) Solutions

5) By Site Management And Monitoring: Site Selection And Initiation, Clinical Monitoring And Site Visits, Patient Recruitment And Retention, Site Training And Support, Site Performance Monitoring

6) By Other Services: Patient Advocacy And Engagement, Real-World Evidence (RWE) Studies, Post-Trial Services, Medical Writing And Documentation, Clinical Trial Auditing And Inspection

What Major Market Trends Are Driving Changes In The Cell And Gene Therapy Clinical Trial Services Market?

Major companies within the cell and gene therapy clinical trial services market are concentrating their efforts on deploying advanced technology, including customer relationship management systems, to enhance efficiency and gain a competitive edge. The customer relationship management system, as employed by cell and gene therapy clinical trial services, streamlines and synchronizes interactions with trial participants, healthcare providers, and other stakeholders across the entire clinical trial process. For instance, in April 2023, AmerisourceBergen Corporation, a healthcare company based in the US, unveiled the Cell and Gene Therapy (CGT) Integration Hub, a platform intended to improve connectivity and rationalize processes throughout the cell and gene therapy treatment pathway. This platform, which is underpinned by AmerisourceBergen’s customer relationship management (CRM) system, endeavors to simplify the path-to-care process, partly by providing physicians and patient services teams with greater visibility across the therapy development and delivery journey. The CGT Integration Hub, featuring elements like expedited benefits investigation, real-time status tracking, and proactive alerts, is designed to simplify care coordination, minimize impediments, and enhance the overall patient and provider experience when delivering cell and gene therapies.

Which Companies Hold Significant Positions In The Cell And Gene Therapy Clinical Trial Services Market?

Major companies operating in the cell and gene therapy clinical trial services market are Thermo Fisher Scientific Inc., Sharp Services LLC, IQVIA, Laboratory Corporation of America Holdings, ICON plc, Syneos Health Inc., Catalent Pharma Solutions Inc., Charles River Laboratories International Inc., Parexel International Corporation, PRA Health Sciences Inc., Covance Inc., Medpace Holdings Inc., BioClinica Inc., Precision Medicine Group LLC, Worldwide Clinical Trials LLC, Clinigen Group plc, Evidera Inc., Advarra LLC, Veristat LLC, Clinipace Inc., Celonic AG, Cromsource Inc., Novotech Pty Ltd., MedSource Holdings Inc., Frontage Laboratories Inc.

Read the full cell and gene therapy clinical trial services market report here:

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

How Does The Cell And Gene Therapy Clinical Trial Services Market Perform Across Major Global Regions?

North America was the largest region in the cell and gene therapy clinical trial services market in 2025. It is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy clinical trial services market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Cell And Gene Therapy Clinical Trial Services Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15535&type=smp

Browse Through More Reports Similar to the Global Cell And Gene Therapy Clinical Trial Services Market 2026, By The Business Research Company

Cell And Gene Therapy Supply Chain Or Logistics Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-supply-chain-or-logistics-global-market-report

Cell And Gene Therapy Clinical Trial Services Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-clinical-trial-services-global-market-report

Cell And Gene Therapy Contract Development And Manufacturing Organization Cdmo Global Market Report

https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model